For months, the DrugRisk Center has reported on growing concern that popular diabetes medications like Januvia, Janumet and Byetta may be linked to increased pancreatic cancer and thyroid cancer.
Now, although top health officials have called for new testing of the drug class, the FDA has reversed course to support the drug makers. This week, the agency said there is not sufficient evidence to show that the drugs increase rates of pancreatic cancer.
The news comes as a shock after repeated reports linking GLP-1 diabetes drugs to cancer. In 2011, researchers at UCLA discovered subjects given Januvia had noticeably higher rates of pancreatic cancer and thyroid cancer.
This year, the American Medical Association warned that drugs like Januvia could double the risk for pancreatitis, which is a leading risk factor for pancreatic cancer. The British Medical Journal reported that these types of diabetes drugs appeared more dangerous than expected, but manufacturers were not taking action to identify risks.
The Institute for Safe Medication Practices warned that FDA reports indicated higher pancreatitis and pancreatic cancer side effects with GLP-1 drugs like Januvia. Also, the American Diabetes Association has called for new clinical trials of diabetes drugs to pinpoint dangers.
As a result of the conflicting reports, experts believe the FDA endorsement may be inaccurate until further testing can be performed.
In the meantime, a growing number of patients have filed a Januvia lawsuit after being diagnosed with pancreatic cancer. A federal panel is deciding whether to consolidate the cases to a special central federal court.
Lawyers are still helping those affected file claims. If you or a loved one were diagnosed with pancreatic cancer or thyroid cancer after taking Januvia or Janumet, it is important to learn about your legal options.
DrugRisk only recommends lawyers who have already handled Januvia lawsuits.
Contact us today for more information on the research, side effects and litigation news related to Januvia, or to speak with a lawyer.